Evidence map›Paper›PMID 38724608›Full record

ArticleScientific reports2024

Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers.

Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rania Mohamed SakrDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt.ORCID http://orcid.org/0009-0004-6592-6602
Abdelaziz El Sayed AbdelazizDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt.ORCID http://orcid.org/0000-0002-4755-6394
Eman Ahmed MazyedDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafr El Sheikh, Egypt. eman_mazyad@pharm.kfs.edu.eg.ORCID http://orcid.org/0000-0002-5606-1115
Gamal Mohamed El MaghrabyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0001-5531-710X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bosentan is a drug used to treat pulmonary hypertension via dual endothelial receptor antagonism. Bosentan has a restricted oral bioavailability, a problem that's mostly due to poor solubility and hepatic metabolism. It is extensively used for the elderly and children who require a friendly dosage form like orodispersible tablets. So, the goal of this research work was to hasten the dissolution rate of bosentan to produce an orodispersible tablet with immediate drug release. Bosentan was exposed to ethanol-assisted kneading with a rise of xylitol or menthol concentrations (1:1 and 1:2 molar ratio of bosentan with excipient). In addition to observing the dissolution behavior, the resulting dry products were investigated using Fourier transform infrared spectroscopy (FTIR), differential thermal analysis (DTA), and X-ray diffraction (XRD). The FTIR reflected possible hydrogen bonding with xylitol and menthol. DSC studies reflected a reduction in the enthalpy and Tm. These results with XRD data reflected partial co-amorphization in the case of xylitol and eutaxia in the case of menthol. These modifications were related to an accelerated dissolving rate. The developed systems were fabricated as orodispersible tablets which exhibited immediate release of bosentan. Thus, the current study offered simple co-processing for the preparation of orodispersible bosentan tablets.

Indexed as

BosentanMentholSolubilityTabletsXylitolAdministration, OralCalorimetry, Differential ScanningDrug CompoundingDrug LiberationExcipientsHumansSpectroscopy, Fourier Transform InfraredX-Ray DiffractionBosentanExcipientsMentholTabletsXylitol

Identifiers

PMID38724608
PMCPMC11082131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.